<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01138995</url>
  </required_header>
  <id_info>
    <org_study_id>CP-L300-0801, Rev. B</org_study_id>
    <nct_id>NCT01138995</nct_id>
  </id_info>
  <brief_title>Clinical Study of the L300 Versus Ankle-foot Orthosis (AFO) on Post-Stroke Subjects With Foot Drop</brief_title>
  <acronym>L300</acronym>
  <official_title>Functional Ambulation: Standard Treatment vs. Electronic Stimulation Therapy (FASTEST)Trial in Chronic Post-Stroke Subjects With Foot Drop</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioness Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medidata Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bioness Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the effectiveness of the NESS L300 (L300) in
      improving gait parameters, function, and quality of life among stroke subjects (greater than
      or equal to 3 months post stroke)with drop foot.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 176 subjects with stroke that have drop foot will be enrolled from
      approximately 10 different sites in the United States depending on the rate of enrollment.
      This clinical study is proposed to show that the functional electrical stimulation (FES)
      delivered via the Ness L300 improves gait function, stroke-specific quality of life, and
      safety for persons with stroke.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ten Meter Walk Test (10mWT)</measure>
    <time_frame>Week 30</time_frame>
    <description>Determine gait velocity during a 10 meter walk test for subjects using the L300 versus subjects using a standard &quot;usual&quot; ankle-foot orthosis (AFO). Long term device effect at comfortable gait speed in m/s. Walk test results at 30 weeks will be compared to baseline speed. The mean difference (improvement) between baseline and week 30 will be presented by study arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Berg Balance Scale (BBS) Score</measure>
    <time_frame>Week 30</time_frame>
    <description>Clinical measurement of balance was recorded using the Berg Balance Scale which is a highly reliable and valid test used among persons with stroke. This Scale consists of 14 items/tasks of increasing difficulty graded on a five-point ordinal scale of zero to four where zero = participant is unable to perform the task and four = participant is independent in performance of task, such that overall total score may range from zero to 56 per participant. Mean Baseline and Mean Week 30 scores were calculated and used to determine change in mean score for each study group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>User Satisfaction</measure>
    <time_frame>Week 30</time_frame>
    <description>Total user satisfaction as measured on 12 item User Satisfaction survey with maximum score 24, minimum 0, where higher score indicated greater satisfaction with device,</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">197</enrollment>
  <condition>Sensorimotor Gait Disorder</condition>
  <condition>Neurologic Ambulation Disorder</condition>
  <condition>Gait, Drop Foot</condition>
  <condition>Poststroke Hemiparesis</condition>
  <condition>Post-Cerebrovascular Accident (CVA) Hemiparesis</condition>
  <arm_group>
    <arm_group_label>Ankle-foot orthosis (AFO) Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Control Group will walk with the a &quot;usual&quot; ankle-foot orthosis (AFO) for 30 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ness L300 Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Original Treatment Group will walk with the Ness L300 for 30 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ness L300</intervention_name>
    <description>The Ness L300 delivers functional electrical stimulation (FES), which improves gait function, stroke-specific quality of life, functionality, and safety for persons with stroke.</description>
    <arm_group_label>Ness L300 Treatment Group</arm_group_label>
    <other_name>Leg Stimulator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ankle-foot orthosis</intervention_name>
    <description>The Control Group will walk with a &quot;usual&quot; ankle-foot orthosis (AFO).</description>
    <arm_group_label>Ankle-foot orthosis (AFO) Control Group</arm_group_label>
    <other_name>drop foot orthotic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have ankle dorsiflexion range of motion greater than or equal to neutral when assessed
             concurrent with test stimulation in sitting and standing and demonstrate adequate
             ankle and knee stability during gait at the time of screening

          -  Have had at least one stroke of any etiology (e.g., ischemic, hemorrhagic,etc.)
             experienced greater than or equal to 3 months prior to study enrollment, as confirmed
             by independent medical records, and result in drop foot sufficient to require prior or
             current prescription for and/or use of an AFO

          -  Have adequate cognition and communication abilities for informed consent, training and
             instructions, use of the L300, and provide feedback, to be demonstrated by either the
             subjects scoring greater than or equal to 24 (out of a possible 30) on the Mini Mental
             State Examination, or having a competent caregiver for these purposes

          -  Must be 18 years or older

          -  Have the ability to safely walk at least 10-meters with a maximum of 1 person assist

          -  Have a self-selected 10-meter gait speed of less than or equal to 0.8m/s at the time
             of assessment

          -  Have inadequate dorsiflexion/limb clearance or unable to achieve normal heel strike on
             ambulation without AFO

          -  Be medically stable

        Exclusion Criteria:

          -  Have fixed ankle contracture at greater than or equal to 5 degrees of plantar flexion
             in the hemiplegic leg with the knee extended

          -  Have excessive pain in the affected leg, as measured by a score greater than or equal
             to 4 on a 10-point visual analog scale

          -  Participation, within the past 3 months, currently, or during the course of the study
             in any interventional clinical studies without the Sponsor's approval

          -  Have a demand-type cardiac pacemaker, defibrillator, or any electrical or metallic
             implant

          -  Have a lower motor neuron disease or injury with inadequate response to stimulation

          -  Have significant swelling/edema in the leg extending up to the knee

          -  Have a history of chronic skin problems/conditions or cancerous lesion present or
             suspected in close proximity ot the expected site for L300 stimulation

          -  Are pregnant or plan on becoming pregnant in the next 45 weeks

          -  Have had botulinum toxin(type a or b) to the hemiplegic leg or arm within the past six
             weeks or plan to have botulinum toxin treatments during the course of the study

          -  Expectation of a significant change in the subject's spasticity medications during the
             course of the study for the effected leg

          -  Have unstable seizure disorder (average of greater or equal to 2 seizures per month)

          -  Have a pre-existing significant orthopedic conditions that are, a that investigator's
             discretion, determined as likely to limit ambulatory progress (e.g., total hip
             replacement [non-metallic], total knee replacement [non-metallic], limited lower
             extremity (LE) range of motion (ROM), rheumatoid arthritis, osteoarthritis, or other
             fracture or dislocation that underlies the expected site for L300 stimulation)

          -  Have a complete hemisensory loss ipsilateral to foot drop

          -  Used the L300 or other FES device for foot drop (e.g., Odstock Drop Foot System
             (ODFS), WalkAide by Innovation Neurotronics, etc.) for greater than or equal to 3
             hours within the last 6 months prior to study enrollment

          -  Have major post-stroke depression (PHQ-9 greater than or equal to 10) that is not
             medically managed with antidepression medication and/or psychotherapy

          -  Currently or planning on participating in a neuro-rehabilitation physical therapy (PT)
             or occupational therapy (OT) program or new independent exercise programs with
             enrolled in the study. However, injury or a change in condition requiring PT or OT
             that would not affect gait outcomes maybe assessed by an off-site study committee, on
             a case-by-case basis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kari Dunning, PT, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>The Drake Center/University of Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael O'Dell, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia Kluding, PT, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven R. Edgley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathaleen P Brady, PT, NCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>MedStar National Rehabilitation Network</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trevor Paris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brooks Rehabilitation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jerome Stenehjem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sharp Rehabilitation Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Thottakara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jun Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Charles Hospital &amp; Rehabilitation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ziyad Ayyoub, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rancho Los Amigos National Rehabilitation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diemha Hoang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Long Beach Memorial Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rancho Los Amigos National Rehabilitation Center</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90242-3496</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach Memorial Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Rehabilitation Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Rehabilitation Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooks Center for Rehabilitation Studies</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Charles Hospital &amp; Rehabilitation</name>
      <address>
        <city>Port Jefferson</city>
        <state>New York</state>
        <zip>11777</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Drake Center /University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah, School of Medicine</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2010</study_first_submitted>
  <study_first_submitted_qc>June 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2010</study_first_posted>
  <results_first_submitted>February 1, 2016</results_first_submitted>
  <results_first_submitted_qc>March 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 28, 2016</results_first_posted>
  <last_update_submitted>March 28, 2016</last_update_submitted>
  <last_update_submitted_qc>March 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Poststroke/CVA hemiparesis</keyword>
  <keyword>Drop Foot</keyword>
  <keyword>Gait Disorders, Neurological</keyword>
  <keyword>Gait, Drop foot</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Paresis</mesh_term>
    <mesh_term>Gait Disorders, Neurologic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Originial Control Group</title>
          <description>The Control Group will walk with the a &quot;usual&quot; ankle-foot orthosis (AFO)for 30 weeks. After 30 weeks, the Original Control Group will then be crossed over to walk with the Ness L300 for a total of 12 weeks.
Ness L300: The Ness L300 delivers functional electrical stimulation (FES), which improves gait function, stroke-specific quality of life, functionality, and safety for persons with stroke.
Ness L300: The Original Treatment Group will walk with the Ness L300 for 42 weeks, and the Original Control Group will walk with a &quot;usual&quot; ankle-foot orthosis (AFO)for 30 weeks, then be crossed over to walk with the Ness L300 for a total of 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Original Treatment Group</title>
          <description>The Original Treatment Group will walk with the Ness L300 for 42 weeks.
Ness L300: The Ness L300 delivers functional electrical stimulation (FES), which improves gait function, stroke-specific quality of life, functionality, and safety for persons with stroke.
Ness L300: The Original Treatment Group will walk with the Ness L300 for 42 weeks, and the Original Control Group will walk with a &quot;usual&quot; ankle-foot orthosis (AFO)for 30 weeks, then be crossed over to walk with the Ness L300 for a total of 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Originial Control Group</title>
          <description>The Control Group will walk with the a &quot;usual&quot; ankle-foot orthosis (AFO)for 30 weeks. After 30 weeks, the Original Control Group will then be crossed over to walk with the Ness L300 for a total of 12 weeks.
Ness L300: The Ness L300 delivers functional electrical stimulation (FES), which improves gait function, stroke-specific quality of life, functionality, and safety for persons with stroke.
Ness L300: The Original Treatment Group will walk with the Ness L300 for 42 weeks, and the Original Control Group will walk with a &quot;usual&quot; ankle-foot orthosis (AFO)for 30 weeks, then be crossed over to walk with the Ness L300 for a total of 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Original Treatment Group</title>
          <description>The Original Treatment Group will walk with the Ness L300 for 42 weeks.
Ness L300: The Ness L300 delivers functional electrical stimulation (FES), which improves gait function, stroke-specific quality of life, functionality, and safety for persons with stroke.
Ness L300: The Original Treatment Group will walk with the Ness L300 for 42 weeks, and the Original Control Group will walk with a &quot;usual&quot; ankle-foot orthosis (AFO)for 30 weeks, then be crossed over to walk with the Ness L300 for a total of 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
            <count group_id="B2" value="99"/>
            <count group_id="B3" value="197"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.6" spread="10.9"/>
                    <measurement group_id="B2" value="60.7" spread="12.2"/>
                    <measurement group_id="B3" value="61.1" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ten Meter Walk Test (10mWT)</title>
        <description>Determine gait velocity during a 10 meter walk test for subjects using the L300 versus subjects using a standard &quot;usual&quot; ankle-foot orthosis (AFO). Long term device effect at comfortable gait speed in m/s. Walk test results at 30 weeks will be compared to baseline speed. The mean difference (improvement) between baseline and week 30 will be presented by study arm.</description>
        <time_frame>Week 30</time_frame>
        <population>Intent to treat analysis of 197 (98 Control and 99 Treatment) randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Originial Control Group</title>
            <description>The Control Group will walk with the a &quot;usual&quot; ankle-foot orthosis (AFO)for 30 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Original Treatment Group</title>
            <description>The Original Treatment Group will walk with the Ness L300 for 30 weeks.
The Ness L300 delivers functional electrical stimulation (FES), which improves gait function, stroke-specific quality of life, functionality, and safety for persons with stroke.</description>
          </group>
        </group_list>
        <measure>
          <title>Ten Meter Walk Test (10mWT)</title>
          <description>Determine gait velocity during a 10 meter walk test for subjects using the L300 versus subjects using a standard &quot;usual&quot; ankle-foot orthosis (AFO). Long term device effect at comfortable gait speed in m/s. Walk test results at 30 weeks will be compared to baseline speed. The mean difference (improvement) between baseline and week 30 will be presented by study arm.</description>
          <population>Intent to treat analysis of 197 (98 Control and 99 Treatment) randomized subjects.</population>
          <units>meters per second (m/s)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.14"/>
                    <measurement group_id="O2" value="0.14" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.75</p_value>
            <method>Fisher's combination test</method>
            <method_desc>Between group difference for entire sample</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Berg Balance Scale (BBS) Score</title>
        <description>Clinical measurement of balance was recorded using the Berg Balance Scale which is a highly reliable and valid test used among persons with stroke. This Scale consists of 14 items/tasks of increasing difficulty graded on a five-point ordinal scale of zero to four where zero = participant is unable to perform the task and four = participant is independent in performance of task, such that overall total score may range from zero to 56 per participant. Mean Baseline and Mean Week 30 scores were calculated and used to determine change in mean score for each study group.</description>
        <time_frame>Week 30</time_frame>
        <population>All randomized subjects are included in this analysis to determine change in mean score from Baseline to Week 30 in each study group.</population>
        <group_list>
          <group group_id="O1">
            <title>Originial Control Group</title>
            <description>The Control Group will walk with the a &quot;usual&quot; ankle-foot orthosis (AFO)for 30 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Original Treatment Group</title>
            <description>The Original Treatment Group will walk with the Ness L300 for 30 weeks.
Ness L300: The Ness L300 delivers functional electrical stimulation (FES), which improves gait function, stroke-specific quality of life, functionality, and safety for persons with stroke.</description>
          </group>
        </group_list>
        <measure>
          <title>Berg Balance Scale (BBS) Score</title>
          <description>Clinical measurement of balance was recorded using the Berg Balance Scale which is a highly reliable and valid test used among persons with stroke. This Scale consists of 14 items/tasks of increasing difficulty graded on a five-point ordinal scale of zero to four where zero = participant is unable to perform the task and four = participant is independent in performance of task, such that overall total score may range from zero to 56 per participant. Mean Baseline and Mean Week 30 scores were calculated and used to determine change in mean score for each study group.</description>
          <population>All randomized subjects are included in this analysis to determine change in mean score from Baseline to Week 30 in each study group.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" spread="4.62"/>
                    <measurement group_id="O2" value="1.97" spread="6.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.022</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>User Satisfaction</title>
        <description>Total user satisfaction as measured on 12 item User Satisfaction survey with maximum score 24, minimum 0, where higher score indicated greater satisfaction with device,</description>
        <time_frame>Week 30</time_frame>
        <population>All randomized subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Originial Control Group</title>
            <description>The Control Group will walk with the a &quot;usual&quot; ankle-foot orthosis (AFO)for 30 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Original Treatment Group</title>
            <description>The Original Treatment Group will walk with the Ness L300 for 30 weeks.
The Ness L300 delivers functional electrical stimulation (FES), which improves gait function, stroke-specific quality of life, functionality, and safety for persons with stroke.</description>
          </group>
        </group_list>
        <measure>
          <title>User Satisfaction</title>
          <description>Total user satisfaction as measured on 12 item User Satisfaction survey with maximum score 24, minimum 0, where higher score indicated greater satisfaction with device,</description>
          <population>All randomized subjects were analyzed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1" spread="4.0"/>
                    <measurement group_id="O2" value="21.8" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for both study arms from Baseline to 30 weeks post-randomization.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Originial Control Group</title>
          <description>The Control Group will walk with the a &quot;usual&quot; ankle-foot orthosis (AFO) for 30 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Original Treatment Group</title>
          <description>The Original Treatment Group will walk with the Ness L300 for 30 weeks.
The Ness L300 delivers functional electrical stimulation (FES), is intended to improve gait function, stroke-specific quality of life, functionality, and safety for persons with stroke.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia requiring blood transfusion</sub_title>
                <description>non device related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>stroke/high blood pressure</sub_title>
                <description>non device related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>bowel obstruction</sub_title>
                <description>non device related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>hospitalization general complaints</sub_title>
                <description>non device related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>cholecystectomy</sub_title>
                <description>non device related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>cancer</sub_title>
                <description>non-device related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>methicillin resistant Staphylococcus aureus</sub_title>
                <description>non device related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone fracture</sub_title>
                <description>non device related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <description>non device related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>mental depression and anxiety</sub_title>
                <description>non device related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>kidney damage due to dehydration</sub_title>
                <description>non device related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>ovarian mass</sub_title>
                <description>non device related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia/respiratory</sub_title>
                <description>non-device related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation or abnormal heartbeat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation and hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea or abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>seasonal allergies</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>blister, folliculitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>fall with or without injury</sub_title>
                <counts group_id="E1" events="71" subjects_affected="45" subjects_at_risk="98"/>
                <counts group_id="E2" events="81" subjects_affected="56" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>gout or diabetes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>joint pain</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="98"/>
                <counts group_id="E2" events="33" subjects_affected="26" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>hypertonia, headache, dizziness, memory deficit</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Fear or depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>asthma, cough, bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>localized skin redness, rash, irritation</sub_title>
                <counts group_id="E1" events="45" subjects_affected="35" subjects_at_risk="98"/>
                <counts group_id="E2" events="68" subjects_affected="45" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension and/or flushing</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Keith McBride, CTO</name_or_title>
      <organization>Bioness</organization>
      <phone>661-362-4866</phone>
      <email>Keith.McBride@bioness.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

